Effectiveness and cost-effectiveness of pembrolizumab in persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS 1-10: secondary analysis of KEYNOTE-826 using innovative KMSubtraction
{{output}}
Background: To evaluate the effectiveness and cost-effectiveness of pembrolizumab combined with chemotherapy and anti-angiogenesis treatment for PD-L1 CPS 1-10 cervical cancer (CC) patients from the perspective of US healthcare p... ...
